Treatment with calcium antagonists does not increase the risk of fatal or non-fatal cancer in an elderly mid-European population: Results from STEPHY II

Journal of Hypertension

Volumn 16, Issue 8, 1998, Pages 1113-1116

  Trenkwalder, Peter ^a   Hendricks, Paul ^b   Hense, Hans Werner ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Calcium antagonists; Cancer; Elderly; Hypertension; Mortality; Side effects

Indexed keywords

CALCIUM ANTAGONIST; DILTIAZEM; FELODIPINE; NIFEDIPINE; NITRENDIPINE; VERAPAMIL;

AGED; ARTICLE; CANCER; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; GERMANY; HUMAN; HYPERTENSION; INCIDENCE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

EID: 0031877888     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816080-00005     Document Type: Article

References (19)

1. Manolio NA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995; 155:829-837
2. Furberg C Psaty B, Meyer J. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92:1326-1331.
3. Pahor M, Guralnik J, Corti M, Foley D, Carbonin P, Havlik R. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995; 43:1191-1197.
4. Pahor M, Guralnik J, Salive M, Corti M, Carbonin P, Havlik R. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9:695-699.
5. Pahor M, Guralnik J, Ferrucci L, Corti M, Salive M, Cerhan J. et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996; 348:493-497.
6. Pahor M, Guralnik J, Furberg C, Carbonin P, Havlik R. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996; 347:1061-1065.
7. Daling JR. Calcium channel blockers and cancer: is an association biologically plausible? Am J Hypertens 1996; 9:713-714.
8. Trenkwalder P, Ruland D, Slender M, Gebhard J, Trenkwalder C, Lydtin H, et al. Prevalence, awareness, treatment and control of hypertension in a population over the age of 65: results from the Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly (STEPHY) J Hypertens 1994; 12:709-716.
9. Trenkwalder P, Ruland D, Lydtin H, Hense HW. Kardiovaskuläre Risikofaktoren bei über 65jährigen in Deutschland. Ergebnisse der STEPHY-Studie (Starnberg Study on Epidemiology of Parkinsonism and Hypertension in the Elderly). Z Kardiol 1994; 83:830-839.
10. Kondo S, Yin D, Morimura T, Kubo H, Nakatsu S, Takeuchi J. Combination therapy with cisplatin and nifedipine induces apoptosis in cisplatin-sensitive and cisplatin-resistant human glioblastoma cells. Br J Cancer 1995; 71:282-289.
11. Balakumaran A, Campbell GA, Moslen MT. Calcium channel blockers induce thymic apoptosis in vivo in rats. Toxicol Appl Pharmacol 1996; 139:122-127.
12. Tijssen JGP, Hugenholtz PG. Critical appraisal of recent studies on nifedipine and other calcium channel blockers in coronary artery disease and hypertension. Eur Heart J 1996; 17:1152-1157
13. Dyer AR, Stamler J, Berkson DM, Lindberg HA, Stevens E. High blood pressure: a risk factor for cancer mortality? Lancet 1971; i:1051-1956.
14. Hamet P. Cancer and hypertension - an unresolved issue. Hypertension 1996; 28:321-324.
15. Wannameethee G, Sharper AG. Blood pressure and cancer in middle-aged British men. Int J Epidemiol 1996; 25:22-31.
16. Borhani NO, Mercuri M, Borhani PA, Buckalew VM, Canossa-Terris M, Carr AA, et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial JAMA 1996; 276:785-791.
17. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium-channel blockers and risk of cancer, Lancet 1997; 349:525-528.
18. Olsen JH, Sorensen HT, Friis S, McLaughlin JK, Steffensen FH, Nielsen GL. et al. Cancer risk in users of calcium channel blockers. Hypertension 1997; 29:1091-1094.
19. Staesen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhäger WH, et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350:757-764